Fluocinolone Acetonide 0.01% Oil Ear Drops

Manufacturer
Seton Pharmaceuticals
Effective date
2024-01-30
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
6
Source
legacy-cache
Hydrated at
2026-08-01 21:12:10

Label at a glance#

ProductFluocinolone acetonide 0.01%
Active ingredientfluocinolone acetonide
Label structure15 sections

Dosage and administration

For the treatment of chronic eczematous external otitis, using the supplied ear-dropper, apply 5 drops of Fluocinolone acetonide 0.01% Oil into the affected ear. To apply, tilt head to one side so that the ear is facing up. Then, gently pull the ear lobe backward and upward and apply 5 drops of Fluocinolone acetonide 0.01% Oil into the ear. Keep head tilted for about a minute to allow Fluocinolone acetonide 0.01% ...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION


For Otic Use Only        NDC13925-508-20
Not for Ophthalmic Use

DESCRIPTION

DESCRIPTION SECTION

Fluocinolone acetonide 0.01% Oil Ear Drops contain fluocinolone acetonide {(6α, 11β, 16α)-6,9-difluoro-11,21-dihydroxy-16,17[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone}, a synthetic corticosteroid.

Chemically, fluocinolone acetonide is C24 H30 F2 O6. It has the following structural formula:

Chemical Structure
Chemical Structure

Fluocinolone acetonide has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water.

Each gram of Fluocinolone acetonide 0.01% Oil Ear Drops contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2, refined peanut oil NF, and fragrances.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Like other topical corticosteroids, fluocinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

PHARMACOKINETICS SECTION

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusion of topical corticosteroids can enhance penetration. Topical corticosteroids can be absorbed from normal intact skin. Also, inflammation and/or other disease processes in the skin can increase percutaneous absorption.

Fluocinolone acetonide 0.01% Oil Ear Drops is in the low to medium range of potency as compared with other topical corticosteroids.

CLINICAL STUDIES

CLINICAL STUDIES SECTION

Efficacy in a placebo-controlled study for the treatment of chronic eczematous external otitis on 154 patients(adults and children 2 years of age and older) treated with five drops per ear of Fluocinolone acetonide 0.01% Oil Ear Drops twice daily, after 7 days of treatment, showed Fluocinolone acetonide 0.01% Oil Ear Drops to be superior to placebo in clearing the signs and symptoms of eczematous external otitis.

Clinical safety studies were conducted on the same formulation of fluocinolone acetonide oil 0.01%. Open-label safety studies on 33 children (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable atopic dermatitis, and baseline body surface area involvement greater than 75% in 18 patients, and 50% to 75% in 15 patients, were treated with Fluocinolone acetonide 0.01% Oil twice daily for 4 weeks. Morning pre-stimulation cortisol level and post-Cortrosyn stimulation cortisol level were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pre-stimulation cortisol levels (3.2 to 6.6 µg/dL; normal: cortisol > 7µg/dL) but all had normal responses to 0.25 mg of Cortrosyn stimulation (cortisol > 18 µg/dL).

A clinical study was conducted to assess the safety of fluocinolone acetonide 0.01% oil, which contains refined peanut oil, on subjects with known peanut allergies. The study enrolled 13 subjects with atopic dermatitis, 6 to 17 years of age. Of the 13 subjects, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The study evaluated the responses to both prick test and patch test utilizing peanut oil NF, fluocinolone acetonide 0.01% oil and histamine/saline controls on the 13 individuals. These subjects were also treated with fluocinolone acetonide 0.01% oil twice daily for 7 days. Prick test and patch test results for all 13 patients were negative to fluocinolone acetonide 0.01% oil and the refined peanut oil. One of the 9 peanut-sensitive patients experienced an exacerbation of atopic dermatitis after 5 days of fluocinolone acetonide 0.01% oil use. Importantly, the bulk peanut oil used in fluocinolone acetonide 0.01% oil is heated at 475°F for at least 15 minutes, which should provide for adequate decomposition of allergenic proteins.

INDICATION AND USAGE

INDICATIONS & USAGE SECTION

Fluocinolone acetonide 0.01% Oil Ear Drops is a low to medium potency corticosteroid indicated for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and older.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Fluocinolone acetonide 0.01% Oil Ear Drops is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

This product contains refined peanut oil NF (see PRECAUTIONS).

PRECAUTIONS

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General: Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.

Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Infrequently, signs and symptoms of glucocorticoid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.

Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS-Pediatric use)

Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than noting a clinical exacerbation, which may occur with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic testing. One peanut sensitive child experienced a flare of his atopic dermatitis after 5 days of twice daily treatment with Fluocinolone acetonide 0.01% Oil (See CLINICAL STUDIES section).

If wheal and flare type reactions (which may be limited to pruritus) or other manifestations of hypersensitivity develop, Fluocinolone acetonide 0.01% Oil Ear Drops should be discontinued immediately and appropriate therapy instituted.

If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Fluocinolone acetonide 0.01% Oil Ear Drops should be discontinued until the infection has been adequately controlled.

Fluocinolone acetonide 0.01% Oil Ear Drops is formulated with 48% refined peanut oil NF. Peanut oil used in this product is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million.

Physicians should use caution in prescribing Fluocinolone acetonide 0.01% Oil Ear Drops for peanut-sensitive individuals.

INFORMATION FOR PATIENTS SECTION

Information for Patients: Patients using topical corticosteroids should receive the following information and instructions:

  1. This medication is to be used as directed by the physician. It is for external use only. Do not use occlusive dressings.
  2. Avoid contact with the eyes. In case of contact, wash eyes liberally with water.
  3. This medication should not be used for any disorder other than that for which it was prescribed.
  4. Patients should promptly report to their physician any worsening of their skin condition.
  5. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician.

LABORATORY TESTS SECTION

Laboratory Tests: The following tests may be helpful in evaluating patients for HPA axis suppression:

ACTH stimulation test
A.M. plasma cortisol test
Urinary free cortisol test

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, mutagenesis, and impairment of fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of Fluocinolone acetonide 0.01% Oil Ear Drops. Studies have not been performed to evaluate the mutagenic potential of fluocinolone acetonide, the active ingredient in Fluocinolone acetonide 0.01% Oil Ear Drops. Some corticosteroids have been found to be genotoxic in various genotoxicity tests (i.e. the in vitro human peripheral blood lymphocyte chromosome aberration assay with metabolic activation, the in vivo mouse bone marrow micronucleus assay, the Chinese hamster micronucleus test and the in vitro mouse lymphoma gene mutation assay).

PREGNANCY SECTION

TERATOGENIC EFFECTS SECTION

Pregnancy: Teratogenic effects: Pregnancy category C: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.

There are no adequate and well-controlled studies in pregnant women on teratogenic effects from Fluocinolone acetonide 0.01% Oil Ear Drops. Therefore, Fluocinolone acetonide 0.01% Oil Ear Drops should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

NURSING MOTHERS SECTION

Nursing Mothers: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fluocinolone acetonide 0.01% Oil Ear Drops is administered to a nursing woman.

PEDIATRIC USE SECTION

Pediatric Use: Fluocinolone acetonide 0.01% Oil Ear Drops may be used twice daily for up to 2 weeks in pediatric patients 2 years of age and older with chronic eczematous external otitis.

Fluocinolone acetonide 0.01% Oil Ear Drops is not recommended for use on the face (See ADVERSE REACTION section).

Because of a higher ratio of skin surface area to body mass, children are at a greater risk than adults of HPA-axis-suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. (See PRECAUTIONS).

HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Fluocinolone acetonide 0.01% Oil Ear Drops is formulated with 48% refined peanut oil NF. Peanut oil used in this product is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million.

Physicians should use caution in prescribing Fluocinolone acetonide 0.01% Oil Ear Drops for peanut-sensitive individuals.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following local adverse reactions have been reported infrequently with topical corticosteroids. They may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria. One peanut sensitive child experienced a flare of his atopic dermatitis after 5 days of twice daily treatment with Fluocinolone acetonide 0.01% Oil.

OVERDOSAGE

OVERDOSAGE SECTION

Topically applied Fluocinolone acetonide 0.01% Oil Ear Drops can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

For the treatment of chronic eczematous external otitis, using the supplied ear-dropper, apply 5 drops of Fluocinolone acetonide 0.01% Oil into the affected ear. To apply, tilt head to one side so that the ear is facing up. Then, gently pull the ear lobe backward and upward and apply 5 drops of Fluocinolone acetonide 0.01% Oil into the ear. Keep head tilted for about a minute to allow Fluocinolone acetonide 0.01% Oil to penetrate lower into the ear canal. Gently pat excess material dripping out of the ear using a clean cotton ball. Follow these instructions twice each day for 7 to 14 days.

HOW SUPPLIED

HOW SUPPLIED SECTION

Fluocinolone acetonide 0.01% Oil Ear Drops is supplied in a 1 fluid ounce bottle containing 20 mL net weight (Dropper Included). (NDC # 13925-508-20).

STORAGE AND HANDLING SECTION

Keep tightly closed. Store at 20°-25° C (68° to 77° F); excursions permitted to 15°-30° C (59°-86°F.) [see USP Controlled Room Temperature].

CAUTION: Rx only

SPL UNCLASSIFIED SECTION

MANUFACTURED BY:
Hill Dermaceuticals, Inc.
Sanford, Florida 32773

FOR:
Seton Pharmaceuticals
Manasquan, NJ 08736
1-800-510-3401

Code: 171G244-1
Date: 01/2014

PRINCIPAL DISPLAY PANEL - 20 mL Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 13925-508-20

Rx only

FLUOCINOLONE
ACETONIDE 0.01% OIL

EAR DROPS

EAR DROPS

For Otic Use Only
Not For Ophthalmic Use

Net contents: 20 mL

SETON
PHARMACEUTICALS

PRINCIPAL DISPLAY PANEL - 20 mL LabelPRINCIPAL DISPLAY PANEL - 20 mL Label

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
13925-508-202024-01-30C16284748780-19d75b9d0-259f-f424-e053-dadaa90a57ceFluocinolone Acetonide 0.01% Oil Ear Drops
13925-508-202020-01-31C16284748780-19d75b9d0-259f-f424-e053-dadaa90a57ceFluocinolone Acetonide 0.01% Oil Ear Drops

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
13925-508-20ML - Milliliter13925-508f284e36f-bf1f-4e3f-a628-c219596ffdc512013-09-04

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
fluocinolone acetonideACTIVE INGREDIENT0CD5FD6S2M2
fluocinolone acetonideACTIVE MOIETY0CD5FD6S2M2
ISOPROPYL ALCOHOLINACTIVE INGREDIENTND2M4163022
ISOPROPYL MYRISTATEINACTIVE INGREDIENT0RE8K4LNJS2
LIGHT MINERAL OILINACTIVE INGREDIENTN6K5787QVP2
OLETH-2INACTIVE INGREDIENT7L6R1SQ6M02
PEANUT OILINACTIVE INGREDIENT5TL50QU0W42

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
13925-50813925-508-20

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 56 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302GEL / TOPICAL75 mgExact identifier — unii candidate
9 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPGEL / TOPICAL20 mgExact identifier — unii candidate
19 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPSUPPOSITORY / VAGINAL1464.9 mgExact identifier — unii candidate
19 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPOIL / AURICULAR (OTIC)419 mgExact identifier — unii candidate
19 equally ranked IID candidates
PEANUT OILPEANUT OIL5TL50QU0W4OIL / TOPICAL3000 mgExact identifier — unii candidate
8 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSOIL / TOPICAL213 mgExact identifier — unii candidate
18 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPEMULSION / TOPICAL68100 mgExact identifier — unii candidate
19 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSCREAM / TOPICAL65000 mgExact identifier — unii candidate
18 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSAEROSOL, SPRAY / TOPICAL6.89 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
PEANUT OILPEANUT OIL5TL50QU0W4CAPSULE / ORAL313.8 mgExact identifier — unii candidate
8 equally ranked IID candidates
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302SOLUTION / TOPICAL40 %w/vExact identifier — unii candidate
9 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSSYSTEM / TRANSDERMAL113 mgExact identifier — unii candidate
18 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSAEROSOL, FOAM / TOPICAL144 mgExact identifier — unii candidate
18 equally ranked IID candidates
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302OIL / TOPICAL72 mgExact identifier — unii candidate
9 equally ranked IID candidates
PEANUT OILPEANUT OIL5TL50QU0W4OIL / AURICULAR (OTIC)498 mgExact identifier — unii candidate
8 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPOIL / TOPICAL2509 mgExact identifier — unii candidate
19 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSFILM / TRANSDERMAL58.08 mgExact identifier — unii candidate
18 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPAEROSOL, FOAM / TOPICAL240 mgExact identifier — unii candidate
19 equally ranked IID candidates
PEANUT OILPEANUT OIL5TL50QU0W4SOLUTION / OPHTHALMICNAExact identifier — unii candidate
8 equally ranked IID candidates
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302SPONGE / TOPICAL4 %w/wExact identifier — unii candidate
9 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSOIL / AURICULAR (OTIC)36 mgExact identifier — unii candidate
18 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPCREAM, AUGMENTED / TOPICAL25 %w/wExact identifier — unii candidate
19 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPPASTE / DENTAL687 mgExact identifier — unii candidate
19 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPTABLET, FILM COATED / ORAL2.49 mgExact identifier — unii candidate
19 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSCREAM / VAGINAL50 mgExact identifier — unii candidate
18 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPCAPSULE / ORAL6 mgExact identifier — unii candidate
19 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPCREAM / TOPICAL456 mgExact identifier — unii candidate
19 equally ranked IID candidates
PEANUT OILPEANUT OIL5TL50QU0W4INJECTION / INTRAMUSCULARNAExact identifier — unii candidate
8 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPTABLET / ORAL7.5 mgExact identifier — unii candidate
19 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSSYSTEM / TOPICAL7 mgExact identifier — unii candidate
18 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPPASTILLE / ORAL3.6 mgExact identifier — unii candidate
19 equally ranked IID candidates
PEANUT OILPEANUT OIL5TL50QU0W4CREAM / TOPICAL10 %w/wExact identifier — unii candidate
8 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSGEL / TOPICAL29 mgExact identifier — unii candidate
18 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSGEL / TRANSDERMAL85 mgExact identifier — unii candidate
18 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSOINTMENT / TOPICAL35 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302LOTION, AUGMENTED / TOPICAL2070 mgExact identifier — unii candidate
9 equally ranked IID candidates
OLETH-2OLETH-27L6R1SQ6M0OIL / TOPICAL190 mgExact identifier — unii candidate
2 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPOINTMENT / TOPICAL1335 mgExact identifier — unii candidate
19 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSGEL, METERED / TRANSDERMAL50 mgExact identifier — unii candidate
18 equally ranked IID candidates
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302TABLET, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
9 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSFILM, EXTENDED RELEASE / TRANSDERMAL20.4 mgExact identifier — unii candidate
18 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPFILM, EXTENDED RELEASE / TRANSDERMAL162 mgExact identifier — unii candidate
19 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPTABLET, COATED / ORAL4.8 mgExact identifier — unii candidate
19 equally ranked IID candidates
OLETH-2OLETH-27L6R1SQ6M0OIL / AURICULAR (OTIC)33 mgExact identifier — unii candidate
2 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSAEROSOL / TOPICAL9.3 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPTABLET, EXTENDED RELEASE / ORAL1 mgExact identifier — unii candidate
19 equally ranked IID candidates
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302SWAB / TOPICAL43.9 %w/wExact identifier — unii candidate
9 equally ranked IID candidates
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302GEL, METERED / TOPICAL525 mgExact identifier — unii candidate
9 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSLOTION / TOPICAL50 mgExact identifier — unii candidate
18 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPSYSTEM / TRANSDERMAL170 mgExact identifier — unii candidate
19 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSSUSPENSION / AURICULAR (OTIC)0.02 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
LIGHT MINERAL OILLIGHT MINERAL OILN6K5787QVPLOTION / TOPICAL48000 mgExact identifier — unii candidate
19 equally ranked IID candidates
ISOPROPYL ALCOHOLISOPROPYL ALCOHOLND2M416302OIL / AURICULAR (OTIC)6 mgExact identifier — unii candidate
9 equally ranked IID candidates
ISOPROPYL MYRISTATEISOPROPYL MYRISTATE0RE8K4LNJSSPRAY / TOPICAL3665 mgExact identifier — unii candidate
18 equally ranked IID candidates
PEANUT OILPEANUT OIL5TL50QU0W4CREAM / VAGINAL9 %w/wExact identifier — unii candidate
8 equally ranked IID candidates
PEANUT OILPEANUT OIL5TL50QU0W4TABLET / ORALNAExact identifier — unii candidate
8 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N019452-001DERMA-SMOOTHE/FSFLUOCINOLONE ACETONIDE0.01%OIL / TOPICALATRLD, RS1988-02-03
N019452-002DERMA-SMOOTHE/FSFLUOCINOLONE ACETONIDE0.01%OIL / TOPICALATRLD, RS2005-11-09
N019452-003DERMOTICFLUOCINOLONE ACETONIDE0.01%OIL/DROPS / OTICATRLD, RS2005-11-09

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 3 matching rows.

Application-product, TE code table
Application-productTE code
N019452-001AT
N019452-002AT
N019452-003AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 132 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-03c2088c7a36db…
2026-10-15 13:18:302026-09N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-09c2088c7a36db…
2026-10-15 13:18:302026-09N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-09c2088c7a36db…
2026-09-14 22:38:342026-08N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-0384e616aacf4f…
2026-09-14 22:38:342026-08N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-0984e616aacf4f…
2026-09-14 22:38:342026-08N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-0984e616aacf4f…
2026-08-18 06:07:402026-07N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-03caaa826d4ba7…
2026-08-18 06:07:402026-07N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-09caaa826d4ba7…
2026-08-18 06:07:402026-07N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-09caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-03011fe1cb6892…
2026-02-19 14:30 UTC2026-02N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-09011fe1cb6892…
2026-02-19 14:30 UTC2026-02N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-09011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-0331067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-0931067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-0931067a03dcf5…
2025-08-23 18:47 UTC2025-08N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-036a471c1ec25d…
2025-08-23 18:47 UTC2025-08N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-096a471c1ec25d…
2025-08-23 18:47 UTC2025-08N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-096a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-03fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-09fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-09fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-03b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-09b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-09b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-0303ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-0903ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-0903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-032680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-092680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-092680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-035bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-095bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-095bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-03d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-09d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-09d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-03d06236e962d9…
2024-10-29 15:01 UTC2024-10N019452-002DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS2005-11-09d06236e962d9…
2024-10-29 15:01 UTC2024-10N019452-003DERMOTIC0.01%OIL/DROPS / OTICATRLD, RS2005-11-09d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N019452-001DERMA-SMOOTHE/FS0.01%OIL / TOPICALATRLD, RS1988-02-0379d66fd596c7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 4 · 132 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09N019452-001AT1c2088c7a36db…
2026-10-15 13:18:302026-09N019452-002AT1c2088c7a36db…
2026-10-15 13:18:302026-09N019452-003AT1c2088c7a36db…
2026-09-14 22:38:342026-08N019452-001AT184e616aacf4f…
2026-09-14 22:38:342026-08N019452-002AT184e616aacf4f…
2026-09-14 22:38:342026-08N019452-003AT184e616aacf4f…
2026-08-18 06:07:402026-07N019452-001AT1caaa826d4ba7…
2026-08-18 06:07:402026-07N019452-002AT1caaa826d4ba7…
2026-08-18 06:07:402026-07N019452-003AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N019452-001AT1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N019452-002AT1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N019452-003AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019452-001AT131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019452-002AT131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019452-003AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08N019452-001AT16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N019452-002AT16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N019452-003AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019452-001AT1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019452-002AT1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019452-003AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019452-001AT1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019452-002AT1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019452-003AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019452-001AT103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019452-002AT103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019452-003AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019452-001AT12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019452-002AT12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019452-003AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019452-001AT15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019452-002AT15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019452-003AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019452-001AT1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019452-002AT1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019452-003AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N019452-001AT1d06236e962d9…
2024-10-29 15:01 UTC2024-10N019452-002AT1d06236e962d9…
2024-10-29 15:01 UTC2024-10N019452-003AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N019452-001AT179d66fd596c7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
5461cc6f-61ed-469c-a707-80ca99f75bfabe70a464-f936-4721-8cbb-b106075bfd4d2025-04-25Adverse reactionsExact identifier
spl set id: be70a464-f936-4721-8cbb-b106075bfd4d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.